Browse TRAF3IP2

Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF08357 SEFIR domain
Function

Could be involved in the activation of both NF-kappa-B via a NF-kappa-B inhibitor kinase (IKK)-dependent mechanism and stress-activated protein kinase (SAPK)/JNK.

> Gene Ontology
 
Biological Process GO:0001783 B cell apoptotic process
GO:0002230 positive regulation of defense response to virus by host
GO:0002377 immunoglobulin production
GO:0002440 production of molecular mediator of immune response
GO:0002697 regulation of immune effector process
GO:0002831 regulation of response to biotic stimulus
GO:0006959 humoral immune response
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0009306 protein secretion
GO:0009615 response to virus
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0048305 immunoglobulin secretion
GO:0050688 regulation of defense response to virus
GO:0050691 regulation of defense response to virus by host
GO:0050792 regulation of viral process
GO:0051607 defense response to virus
GO:0070227 lymphocyte apoptotic process
GO:0071887 leukocyte apoptotic process
GO:0098542 defense response to other organism
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TRAF3IP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TRAF3IP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TRAF3IP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.3540.000355
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1820.454
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.4910.143
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1170.661
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0420.984
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2140.933
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0630.874
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0890.952
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2840.867
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1280.932
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0290.99
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2460.00452
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TRAF3IP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRAF3IP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRAF3IP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRAF3IP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRAF3IP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TRAF3IP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TRAF3IP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTRAF3IP2
NameTRAF3 interacting protein 2
Aliases DKFZP586G0522; ACT1; CIKS; C6orf4; C6orf5; C6orf6; C6orf2; chromosome 6 open reading frame 5; chromosome 6 o ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TRAF3IP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.